Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
30.20
-2.34 (-7.19%)
Nov 20, 2026, 4:00 PM EST - Market closed
Nektar Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Nektar Therapeutics stock has a consensus rating of "Buy" and an average price target of $131.92. The average 1-year stock price forecast is 336.82% higher than the current stock price, while the lowest is $40 (+32.45%) and the highest is $192 (+535.76%).
Price Target: $131.92 (+336.82%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Nektar Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 9 | 10 | 10 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 2 | 2 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 12 | 12 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $153 → $149 | Buy | Reiterates | $153 → $149 | +393.38% | Nov 16, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $185 | Buy | Maintains | $185 | +512.58% | Nov 16, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $130 | Buy | Reiterates | $130 | +330.46% | Nov 13, 2026 |
| Wedbush | Wedbush | Hold Maintains $50 → $40 | Hold | Maintains | $50 → $40 | +32.45% | Nov 13, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $192 | Buy | Maintains | $192 | +535.76% | Nov 13, 2026 |
Financial Forecast
Revenue This Year
40.52M
from 55.23M
Decreased by -26.63%
Revenue Next Year
51.16M
from 40.52M
Increased by 26.26%
EPS This Year
-7.19
from -8.66
EPS Next Year
-9.93
from -7.19
EPS and Forward PE are based on non-GAAP adjusted numbers.